Tributyrin

Tributyrin (glycerol tributyrate, CAS 60-01-5) is the 1,2,3-tributanoyl ester of glycerol and the principal triglyceride prodrug of butyric acid studied in human clinical pharmacology and preclinical oncology. Classified by the United States Food and Drug Administration as Generally Recognized as Safe (GRAS) for food use, tributyrin is a naturally occurring lipid constituent of bovine milk fat and honey that has attracted sustained research interest as a vehicle for delivering pharmacologically active butyrate concentrations to systemic circulation and to the colonic epithelium, overcoming the rapid first-pass hepatic clearance, objectionable odor, and poor oral bioavailability that limit the therapeutic application of free butyric acid and its sodium salt.

The molecular pharmacology of tributyrin is mediated through its hydrolytic product, butyrate, a four-carbon short-chain fatty acid that operates through at least three characterized molecular mechanisms: inhibition of class I and class II histone deacetylases (HDACs), particularly HDAC1, HDAC2, and HDAC3; agonism at the G-protein-coupled receptor GPR109A (also designated HCAR2 or HM74a), the niacin receptor expressed on colonocytes, adipocytes, and immune cells; and agonism at the free fatty acid receptors GPR41 (FFAR3) and GPR43 (FFAR2) on enteroendocrine cells and immune cells. The HDAC-inhibitory activity produces histone hyperacetylation, chromatin remodeling, and consequent transcriptional activation of tumor suppressor genes (p21WAF1/CIP1, BAX, p53), cell cycle arrest proteins, and differentiation-associated gene programs in neoplastic cells. The GPR109A agonism mediates anti-inflammatory signaling through suppression of NF-kappaB-dependent proinflammatory cytokine production and through promotion of regulatory T-cell and M2-macrophage phenotypes in adipose tissue and intestinal lamina propria.

Two Phase I clinical trials in patients with advanced solid tumors have characterized the human pharmacology of tributyrin. The Conley et al. (1998) study administered tributyrin at 50 to 400 mg/kg orally to 13 patients and demonstrated dose-proportional plasma butyrate concentrations reaching 0 to 0.45 mM, with no dose-limiting toxicity. The Edelman et al. (2003) study administered tributyrin at 150 to 200 mg/kg in the published literature to 20 patients with advanced solid tumors and achieved median plasma butyrate concentrations of 52 micromolar with considerable interpatient variability; escalation was halted at 200 mg/kg in the published literature owing to the large number of capsules required rather than to toxicity. Both trials confirmed that tributyrin is well tolerated, with mild gastrointestinal complaints (nausea, eructation, diarrhea) as the principal adverse events.

Preclinical pharmacology spans oncology, gastroenterology, hepatology, metabolic disease, and muscle biology. In oncology, tributyrin induces differentiation, growth arrest, and apoptosis in human prostate cancer (PC3, LNCaP, TSU-Pr1), colon cancer (HT-29, Caco-2), breast cancer (MCF-7), and leukemia cell lines at concentrations of 0.1 to 4 mM, and suppresses hepatocarcinogenesis in the resistant hepatocyte rat model through p53 acetylation and activation of the p53 apoptotic signaling pathway. In gastroenterology, tributyrin maintains intestinal tight junction integrity, reduces antibiotic-induced intestinal injury in combination with Lactobacillus GG, and mitigates chronic-binge ethanol-induced intestinal barrier disruption and liver injury. In metabolic disease, tributyrin attenuates obesity-associated inflammation, improves insulin responsiveness, and reduces hepatic triglyceride accumulation through a GPR109A-dependent mechanism. In muscle biology, dietary tributyrin promotes satellite cell terminal differentiation through HDAC inhibition and epigenetic priming, producing measurable increases in muscle fiber cross-sectional area in neonatal piglet models.

This monograph reviews the chemistry, synthesis, and physicochemical properties of tributyrin; the three-arm molecular pharmacology (HDAC inhibition, GPR109A agonism, FFAR agonism); the human pharmacokinetic record from Phase I oncology trials; the preclinical evidence base across oncology, gastrointestinal, hepatoprotective, metabolic, and muscle biology applications; sourcing and quality verification for research use; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative butyrate delivery forms against tributyrin on five competency standards (bioavailability, effect size, delivery specificity, tolerability profile, and overall validation). The compound is not approved as a drug by any regulatory authority. It is sold as a dietary supplement and as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.